CymaBay Therapeutics (CBAY) Insider Trading & Ownership → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free CBAY Stock Alerts $32.48 0.00 (0.00%) (As of 04/1/2024) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability CymaBay Therapeutics (NASDAQ:CBAY) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.00%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$7.81 M Get CBAY Insider Trade Alerts Want to know when executives and insiders are buying or selling CymaBay Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CBAY Insider Buying and Selling by Quarter Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… CymaBay Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/12/2024Janet DorlingDirectorSell6,000$31.97$191,820.00 1/19/2024Charles McwherterInsiderSell18,403$23.67$435,599.01 1/16/2024Daniel MenoldVPSell10,000$23.58$235,800.00 1/16/2024Paul T. QuinlanGeneral CounselSell5,000$23.58$117,900.00 1/10/2024Janet DorlingDirectorSell6,000$23.86$143,160.00 12/18/2023Charles McwherterInsiderSell11,332$21.48$243,411.36 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/15/2023Daniel MenoldVPSell21,497$21.99$472,719.03 12/15/2023Paul T. QuinlanGeneral CounselSell5,000$21.98$109,900.00 12/11/2023Janet DorlingDirectorSell6,000$20.07$120,420.00 12/11/2023Sujal ShahCEOSell64,865$20.00$1,297,300.00 11/17/2023Charles McwherterInsiderSell11,342$18.28$207,331.76 11/15/2023Paul T. QuinlanGeneral CounselSell5,000$17.38$86,900.00 10/18/2023Charles McwherterInsiderSell21,743$14.07$305,924.01 10/16/2023Paul T. QuinlanGeneral CounselSell5,000$13.76$68,800.00 10/9/2023Sujal ShahCEOSell64,861$14.20$921,026.20 9/29/2023Kurt Von EmsterDirectorSell15,921$15.68$249,641.28 9/18/2023Charles McwherterInsiderSell21,746$16.22$352,720.12 9/15/2023Paul T. QuinlanGeneral CounselSell53,000$16.87$894,110.00 8/18/2023Charles McwherterInsiderSell21,746$11.47$249,426.62 8/15/2023Paul T. QuinlanGeneral CounselSell5,000$11.91$59,550.00 8/9/2023Daniel MenoldVPSell20,945$12.35$258,670.75 7/18/2023Charles McwherterInsiderSell21,749$11.43$248,591.07 7/14/2023Paul T. QuinlanGeneral CounselSell5,000$11.81$59,050.00 6/30/2023Paul T. QuinlanGeneral CounselSell5,000$10.05$50,250.00 6/20/2023Charles McwherterInsiderSell21,749$8.16$177,471.84 5/18/2023Charles McwherterInsiderSell21,749$9.08$197,480.92 5/15/2023Paul T. QuinlanGeneral CounselSell5,000$10.37$51,850.00 (Data available from 1/1/2013 forward) CBAY Insider Trading Activity - Frequently Asked Questions Who is on CymaBay Therapeutics's Insider Roster? The list of insiders at CymaBay Therapeutics includes Charles Mcwherter, Daniel Menold, Dennis D Kim, Janet Dorling, Kurt Von Emster, Paul T. Quinlan, and Sujal Shah. Learn more on insiders at CBAY. What percentage of CymaBay Therapeutics stock is owned by insiders? 7.00% of CymaBay Therapeutics stock is owned by insiders. Learn more on CBAY's insider holdings. Which CymaBay Therapeutics insiders have been buying company stock? The following insider purchased CBAY shares in the last 24 months: Sujal Shah ($100,036.95). How much insider buying is happening at CymaBay Therapeutics? Insiders have purchased a total of 51,301 CBAY shares in the last 24 months for a total of $100,036.95 bought. Which CymaBay Therapeutics insiders have been selling company stock? The following insiders have sold CBAY shares in the last 24 months: Charles Mcwherter ($2,417,956.71), Daniel Menold ($967,189.78), Dennis D Kim ($1,141,340.64), Janet Dorling ($455,400.00), Kurt Von Emster ($249,641.28), Paul T. Quinlan ($1,498,310.00), and Sujal Shah ($2,218,326.20). How much insider selling is happening at CymaBay Therapeutics? Insiders have sold a total of 600,748 CymaBay Therapeutics shares in the last 24 months for a total of $8,948,164.61 sold. More Insider Trading Tools from MarketBeat Related Companies: INSM Insider Transactions BHVN Insider Transactions RARE Insider Transactions ALKS Insider Transactions PRGO Insider Transactions PBH Insider Transactions NUVL Insider Transactions AXSM Insider Transactions ALPN Insider Transactions BHC Insider Transactions Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: The 5 Stocks Most Sold By Insiders This Year3 Cheap Stocks Insiders are Buying: Investors Should Avoid 1The 5 Hottest CEO Stock Purchases So Far This Year3 Cheap Stocks that Insiders Bought in Q1Michael Burry Picked a Winner With GEN Restaurant Group This page (NASDAQ:CBAY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
